| Trial ID # | NCT01802749; MITO16B-MaNGO OV2B |
| Phase | III |
| Drug Class | Angiogenesis Inhibitors: VEGF |
| Drug Name | Bevacizumab |
| Alternate Drug Names | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin |
| Drugs in Trial | Carboplatin, Liposomal doxorubicin, Paclitaxel, Bevacizumab, Gemcitabine |
| Eligible Participant | Platinum sensitive ovarian cancer after first-line treatment incl. bevacizumab (recurrence or progression either during or after bevacizumab as maintenance) |
| Patients Enrolled | 406 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Randomized |
| Endpoints | ORR, PFS, OS, evaluated per RECIST |
| Efficacy | CarboPt+Pac+Bev vs CarboPt+Pac: ORR: 74.6 (20CR, 77PR) vs 65.7% (9CR, 85PR) |
| Clinically Significant Adverse Events | CarboPt+Pac+Bev vs CarboPt+Pac: |
| Conclusion | Rechallenge with bevacizumab in combination with platinum-based doublets is associated with a significantly prolonged PFS |
| Reference | Pignata S et al. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trialMITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol (2018) 36 (suppl; abstr 5506) Pignata S et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol (2021) 22(2):267-276 |